SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.
Commenting on the patent issuance, Mr. William P. Spencer, President of Imagenetix, said, "The issuance is a significant development relating to our novel technology in the therapeutic treatment of periodontal disease and other inflammatory related conditions. Imagenetix now owns a broader range of intellectual property protection on our novel technology with the issuance of this U.S. patent. Through the guidance of Imagenetix's scientists and consultants, who are experts in achieving drug approval in this field, we continue to move forward with our promising drug therapy for the treatment of periodontitis."
Imagenetix's early stage drug candidate (1-TDC) has been studied at Boston University's Department of Periodontology and Oral Biology for the treatment of periodontal disease. In studies published in the Journal of Periodontology, 1-TDC was shown to stop the progression of periodontal disease in a rabbit periodontitis model. Studies at Boston University also demonstrated significant improvement and restoration in tissue and bone health compared to the placebo group.
Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates proprietary over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.
Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.
Contact Imagenetix Investor Relations William P. Spencer (858)385-2797 Chief Executive Officer Imagenetix, Inc. Tel: (858) 674-8455
SOURCE Imagenetix, Inc.
|SOURCE Imagenetix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved